Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Allegra-D · 1 trial · 1 indication
Acoustic rhinometry: a technique intended for assessment of the geometry of nasal cavity and nasopharynx and for evaluating nasal obstruction. At each time point, there were 2 acoustic rhinometry measurements taken, one for each nostril. Mean of the left and right nostril measurements was taken as measurement at each time point. Minimum Cross-Sectional Area (Amin) at Baseline was defined as mean of 3, 'post-diluent, pre-allergen challenge' measures for each intervention period at 2 hours (hrs) 10 minutes (min), 2 hrs 25 min and 2 hrs 40 min post PF-03654746/placebo dose. Amin 'post-allergen challenge' measures recorded at 2 hrs 55 min, 3 hrs 10 min and 3 hrs 25 min post PF-03654746/placebo dose for each intervention period was averaged to derive single 'post-allergen challenge' value. Amin proportion was defined as ratio of 'post-allergen challenge' value and 'Baseline/pre-allergen challenge value'. Diluent used was saline and allergen was short ragweed extract.
Acoustic rhinometry: a technique intended for assessment of the geometry of nasal cavity and nasopharynx and for evaluating nasal obstruction. At each time point, there were 2 acoustic rhinometry measurements taken, one for each nostril. Mean of the left and right nostril measurements was taken as measurement at each time point. Nasal volume at Baseline was defined as mean of 3, 'post-diluent, pre-allergen challenge' measures for each intervention period at 2 hrs 10 min, 2 hrs 25 min and 2 hrs 40 min post PF-03654746/placebo dose. Nasal volume 'post-allergen challenge' measures recorded at 2 hrs 55 min, 3 hrs 10 min and 3 hrs 25 min post PF-03654746/placebo dose for each intervention period was averaged to derive single 'post-allergen challenge' value. Nasal volume proportion was defined as ratio of 'post-allergen challenge' value and 'Baseline/pre-allergen challenge value'. Diluent used was saline and allergen was short ragweed extract.
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | - |
| Allegra | ACTIVE_COMPARATOR | - |
| Allegra-D | ACTIVE_COMPARATOR | - |
| PF-03654746 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | A single oral dose of Placebo is dosed during the study in order to ascertain the effect of placebo on measures and in order to maintain the blind of the other drugs. |
| Allegra | DRUG | A single oral dose of Allegra is dosed to subjects in combination with PF-03654746. |
| Allegra-D | DRUG | A single oral dose of Allegra-D is dosed to subjects as an active comparator. |
| PF-03654746 | DRUG | A single oral dose of PF-03654746 is the investigational drug being studied. |
Inclusion Criteria: * Male or female subjects 19-55 years with allergic rhinitis requiring treatment within the previous 2 years. * Subjects that respond to a ragweed nasal allergen challenge at screening. Exclusion Criteria: * History of asthma or FEV1 \< 80% predicted. * Significant concomitant...
Top 1 of 3 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 1 | PHASE3 | LY3650150 |
Allegra-D is being studied for allergic rhinitis. It is an investigational small molecule developed by Pfizer, Inc. (NYSE: PFE). The clinical program has focused on patients with allergic rhinitis, and the drug has been tested in a Phase 2 trial.
Allegra-D is developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer is the sponsor of the clinical trial evaluating Allegra-D in allergic rhinitis.
Allegra-D is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA for any indication. The Phase 2 trial has been completed.
Allegra-D has been evaluated in one completed Phase 2 trial, NCT00562120, titled "A Study to Test a New Decongestant in Patients With Allergic Rhinitis Following a Nasal Allergen Challenge." The trial enrolled 21 participants in the United States and was randomized, double-blind, and placebo-controlled.
Allegra-D is a small molecule being studied as a decongestant for allergic rhinitis. Its specific molecular target has not been disclosed. The Phase 2 trial was designed to test a new decongestant in patients with allergic rhinitis following a nasal allergen challenge.